Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study of PLB-002 (Anti-Claudin 6 ADC) in Adults With Advanced Solid Tumors

NCT07304128 is registered in ClinicalTrials.gov with Primelink BioTherapeitics(ShenZhen) Limited as lead sponsor.

NCT NCT07304128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07304128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study of PLB-002 (Anti-Claudin 6 ADC) in Adults With Advanced Solid Tumors
Lead sponsor
Primelink BioTherapeitics(ShenZhen) Limited
Phase
Phase 1
Overall status
Recruiting
Start date
February 6, 2026
Completion date
December 30, 2027
Enrollment
100 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor